ArticleVaccine2012
Role of antibody dependent cell mediated cytotoxicity (ADCC) in Sm-p80-mediated protection against Schistosoma mansoni.
Article in Vaccine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 32 citations in OpenAlex.
- Evaluating the Immunoprotective and Diagnostic Potential of Schistosoma mansoni Epitopes from Sm050890 and Sm141290 Proteins Identified Through Reverse Vaccinology.Acta parasitologica · 2025Article
- Single-cell RNA-sequencing of peripheral blood mononuclear cells reveals the transcriptome profile ofFrontiers in cellular and infection microbiology · 2025Article
- Article
- Pulmonary inflammation promoted by type-2 dendritic cells is a feature of human and murine schistosomiasis.Nature communications · 2023Article
- Schistosoma mansoni egg-derived extracellular vesicles: A promising vaccine candidate against murine schistosomiasis.PLoS neglected tropical diseases · 2021Article
- Recent Advances and Methodological Considerations on Vaccine Candidates for Human Schistosomiasis.Frontiers in tropical diseases · 2021Article
- Evolution of Cellular Immunity Effector Cells; Perspective on Cytotoxic and Phagocytic Cellular Lineages.Cells · 2021Review
- A comprehensive and critical overview of schistosomiasis vaccine candidates.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2021Review
- Promising Technologies in the Field of Helminth Vaccines.Frontiers in immunology · 2021Review
- Searching for the one(s): Using Probiotics as Anthelmintic Treatments.Frontiers in pharmacology · 2021Review
- Characteristics and function of cathepsin L3 from Schistosoma japonicum.Parasitology research · 2020Article
- Monocyte and Macrophage-Mediated Pathology and Protective Immunity During Schistosomiasis.Frontiers in microbiology · 2020Review
- Sm16, AJournal of immunology research · 2019Article
- Cross-species prophylactic efficacy of Sm-p80-based vaccine and intracellular localization of Sm-p80/Sm-p80 ortholog proteins during development in Schistosoma mansoni, Schistosoma japonicum, and Schistosoma haematobium.Parasitology research · 2017Article
- Development of a schistosomiasis vaccine.Expert review of vaccines · 2016Review
- A vaccine consisting of Schistosoma mansoni cathepsin B formulated in Montanide ISA 720 VG induces high level protection against murine schistosomiasis.BMC infectious diseases · 2016Article
- Sm29, but not Sm22.6 retains its ability to induce a protective immune response in mice previously exposed to a Schistosoma mansoni infection.PLoS neglected tropical diseases · 2015Article
- Distribution of Peripheral Memory T Follicular Helper Cells in Patients with Schistosomiasis Japonica.PLoS neglected tropical diseases · 2015Article
- Eliminating Schistosomes through Vaccination: What are the Best Immune Weapons?Frontiers in immunology · 2015Review
- Functions of Antibodies.Microbiology spectrum · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Schistosomiasis is a major health problem in the developing world and for international travelers to the endemic countries. Existing strategies to control schistosomiasis have had limited successes so far. The addition of an effective vaccine in existing control measures would be greatly beneficial in reducing the impact of the disease. In this regard, Sm-p80 mediated protection against intestinal schistosomiasis caused by Schistosoma mansoni has been observed to be promising in two animal models of infection and disease. In this study, the role of antibody dependent cell mediated cytotoxicity (ADCC) was deciphered in Sm-p80-mediated protection especially in the elimination of lung stage schistosomula. This was achieved using lung lavage cells and lung cells that were isolated from mice immunized with and without Sm-p80 formulated in a recombinant vaccine formulation. Significant differences were observed in cytotoxicity assays using immune sera with the lung lavage cells which showed 51% more killing of schistosomula and elevated levels of nitric oxide in the supernatants were detected compared to controls.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.